Correspondence | Published:

Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis

Bone Marrow Transplantationvolume 53pages770773 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis. 1995;18:398–412.

  2. 2.

    Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2:709–12.

  3. 3.

    Boelens JJ, Wynn RF, O’Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–33.

  4. 4.

    Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990;322:1860–6.

  5. 5.

    Rovelli AM. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant. 2008;41(Suppl 2):S87–9.

  6. 6.

    Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol. 2014;167:293–303.

  7. 7.

    Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.

  8. 8.

    Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124:843–50.

  9. 9.

    Qin XY, Li GX, Qin YZ, Wang Y, Wang FR, Liu DH, et al. Quantitative assessment of hematopoietic chimerism by quantitative real-time polymerase chain reaction of sequence polymorphism systems after hematopoietic stem cell transplantation. Chin Med J (Engl). 2011;124:2301–8.

  10. 10.

    Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1105–17.

  11. 11.

    Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol. 1991;9:175–88.

  12. 12.

    Keating MJ, O’Brien S, Lerner S, Koller C, Beran M, Robertson LE, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–71.

  13. 13.

    Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood. 1998;91:2601–8.

  14. 14.

    Miller WP, Rothman SM, Nascene D, Kivisto T, DeFor TE, Ziegler RS, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118:1971–8.

  15. 15.

    Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164–72.

Download references

Acknowledgements

Medical editors at Editage provided editing assistance to the authors during the preparation of this manuscript. This work was supported by the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81621001), the National Natural Science Foundation of China (81530046), and the Science and Technology Project of Guangdong Province of China (2016B030230003).

Author information

Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China

    • Yao Chen
    • , Lan-Ping Xu
    • , Xiao-Hui Zhang
    • , Huan Chen
    • , Feng-Rong Wang
    • , Kai-Yan Liu
    •  & Xiao-Jun Huang
  2. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, China

    • Yao Chen
    • , Lan-Ping Xu
    • , Xiao-Hui Zhang
    • , Huan Chen
    • , Feng-Rong Wang
    • , Kai-Yan Liu
    •  & Xiao-Jun Huang
  3. Department of Pediatrics, Peking University People’s Hospital, Beijing, China

    • Jiong Qin
  4. Department of Pediatrics, Peking University First Hospital, Beijing, China

    • Yan-Ling Yang

Authors

  1. Search for Yao Chen in:

  2. Search for Lan-Ping Xu in:

  3. Search for Xiao-Hui Zhang in:

  4. Search for Huan Chen in:

  5. Search for Feng-Rong Wang in:

  6. Search for Kai-Yan Liu in:

  7. Search for Jiong Qin in:

  8. Search for Yan-Ling Yang in:

  9. Search for Xiao-Jun Huang in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Xiao-Jun Huang.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41409-018-0175-8